133 related articles for article (PubMed ID: 38286352)
1. CFHR1 involvement in bile duct carcinoma: Insights from a data mining study.
Liu Y; Shen T; Liu J; Yu X; Li Q; Chen T; Jiang T
Anal Biochem; 2024 May; 688():115474. PubMed ID: 38286352
[TBL] [Abstract][Full Text] [Related]
2.
Wu J; Guo Y; Zuo ZF; Zhu ZW; Han L
World J Gastroenterol; 2023 May; 29(19):2961-2978. PubMed ID: 37274806
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel mutation gene signature HAMP for cholangiocarcinoma through comprehensive TCGA and GEO data mining.
Wang Z; Du Y
Int Immunopharmacol; 2021 Oct; 99():108039. PubMed ID: 34426102
[TBL] [Abstract][Full Text] [Related]
4. Upregulated lncRNA-UCA1 contributes to metastasis of bile duct carcinoma through regulation of miR-122/
Kong L; Wu Q; Zhao L; Ye J; Li N; Yang H
Cell Cycle; 2019 Jun; 18(11):1212-1228. PubMed ID: 31106658
[TBL] [Abstract][Full Text] [Related]
5. microRNA-329 suppresses epithelial-to-mesenchymal transition and lymph node metastasis in bile duct cancer by inhibiting laminin subunit beta 3.
Liao CH; Liu Y; Wu YF; Zhu SW; Cai RY; Zhou L; Yin XM
J Cell Physiol; 2019 Aug; 234(10):17786-17799. PubMed ID: 30887508
[TBL] [Abstract][Full Text] [Related]
6. A novel three‑miRNA signature predicts survival in cholangiocarcinoma based on RNA‑Seq data.
Cao J; Sun L; Li J; Zhou C; Cheng L; Chen K; Yan B; Qian W; Ma Q; Duan W
Oncol Rep; 2018 Sep; 40(3):1422-1434. PubMed ID: 29956786
[TBL] [Abstract][Full Text] [Related]
7. PNOC Expressed by B Cells in Cholangiocarcinoma Was Survival Related and LAIR2 Could Be a T Cell Exhaustion Biomarker in Tumor Microenvironment: Characterization of Immune Microenvironment Combining Single-Cell and Bulk Sequencing Technology.
Chen Z; Yu M; Yan J; Guo L; Zhang B; Liu S; Lei J; Zhang W; Zhou B; Gao J; Yang Z; Li X; Zhou J; Fan J; Ye Q; Li H; Xu Y; Xiao Y
Front Immunol; 2021; 12():647209. PubMed ID: 33841428
[TBL] [Abstract][Full Text] [Related]
8. A metabolism-related 4-lncRNA prognostic signature and corresponding mechanisms in intrahepatic cholangiocarcinoma.
Zou W; Wang Z; Wang F; Li L; Liu R; Hu M
BMC Cancer; 2021 May; 21(1):608. PubMed ID: 34034689
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of perihilar cholangiocarcinoma: hilar bile duct cancer versus intrahepatic cholangiocarcinoma involving the hepatic hilus.
Sano T; Shimada K; Sakamoto Y; Ojima H; Esaki M; Kosuge T
Ann Surg Oncol; 2008 Feb; 15(2):590-9. PubMed ID: 18057991
[TBL] [Abstract][Full Text] [Related]
10. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways.
Schlitter AM; Born D; Bettstetter M; Specht K; Kim-Fuchs C; Riener MO; Jeliazkova P; Sipos B; Siveke JT; Terris B; Zen Y; Schuster T; Höfler H; Perren A; Klöppel G; Esposito I
Mod Pathol; 2014 Jan; 27(1):73-86. PubMed ID: 23828315
[TBL] [Abstract][Full Text] [Related]
11. Identification of Prognostic Factors in Cholangiocarcinoma Based on Integrated ceRNA Network Analysis.
Jin H; Liu W; Xu W; Zhou L; Luo H; Xu C; Chen X; Chen W
Comput Math Methods Med; 2022; 2022():7102736. PubMed ID: 36158120
[TBL] [Abstract][Full Text] [Related]
12. A2M is a potential core gene in intrahepatic cholangiocarcinoma.
Zhang G; Liu X; Sun Z; Feng X; Wang H; Hao J; Zhang X
BMC Cancer; 2022 Jan; 22(1):5. PubMed ID: 34979994
[TBL] [Abstract][Full Text] [Related]
13. A Cholangiocarcinoma Prediction Model Based on Random Forest and Artificial Neural Network Algorithm.
Liao J; Meng C; Liu B; Zheng M; Qin J
J Coll Physicians Surg Pak; 2023 May; 33(5):578-586. PubMed ID: 37190696
[TBL] [Abstract][Full Text] [Related]
14. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features.
Liau JY; Tsai JH; Yuan RH; Chang CN; Lee HJ; Jeng YM
Mod Pathol; 2014 Aug; 27(8):1163-73. PubMed ID: 24406866
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker.
Utispan K; Thuwajit P; Abiko Y; Charngkaew K; Paupairoj A; Chau-in S; Thuwajit C
Mol Cancer; 2010 Jan; 9():13. PubMed ID: 20096135
[TBL] [Abstract][Full Text] [Related]
16. Cholangiocarcinoma: new insights into disease pathogenesis and biology.
Braconi C; Patel T
Infect Dis Clin North Am; 2010 Dec; 24(4):871-84, vii. PubMed ID: 20937455
[TBL] [Abstract][Full Text] [Related]
17. Expression and prognostic value of soluble CD97 and its ligand CD55 in intrahepatic cholangiocarcinoma.
Meng ZW; Liu MC; Hong HJ; Du Q; Chen YL
Tumour Biol; 2017 Mar; 39(3):1010428317694319. PubMed ID: 28345461
[TBL] [Abstract][Full Text] [Related]
18. Integrated pan-cancer analysis of centromere protein F and experimental verification of its role and clinical significance in cholangiocarcinoma.
Cao Z; Zeng L; Wang Z; Wen X; Zhang J
Funct Integr Genomics; 2023 May; 23(2):190. PubMed ID: 37247093
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of microRNA-203 in cholangiocarcinoma.
Li J; Gao B; Huang Z; Duan T; Li D; Zhang S; Zhao Y; Liu L; Wang Q; Chen Z; Cheng K
Int J Clin Exp Pathol; 2015; 8(8):9512-6. PubMed ID: 26464713
[TBL] [Abstract][Full Text] [Related]
20. Developing metabolic gene signatures to predict intrahepatic cholangiocarcinoma prognosis and mining a miRNA regulatory network.
Ran X; Luo J; Zuo C; Huang Y; Sui Y; Cen J; Tang S
J Clin Lab Anal; 2022 Jan; 36(1):e24107. PubMed ID: 34871464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
